Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409666 | 0.85 | IDO1 (0.43) | IDO1GPR119RORCTACR1DPP4 | |
| SCHEMBL21723050 | 0.85 | MGLL (0.51) | GPR119RORCTACR1DPP4MAPT | |
| SCHEMBL19833730 | 0.83 | CHRNA7 (0.53) | GPR119RORCTACR1MAPTNAMPT | |
| SCHEMBL22462905 | 0.81 | RORC (0.43) | GPR119RORCTACR1DPP4MAPT | |
| SCHEMBL29962387 | 0.81 | IDO1 (0.42) | IDO1GPR119RORCTACR1DPP4 | |
| SCHEMBL25327924 | 0.80 | SCN9A (0.48) | GPR119RORCTACR1DPP4MAPT | |
| SCHEMBL25259349 | 0.80 | TACR1 (0.47) | GPR119RORCTACR1DPP4MAPT | |
| SCHEMBL28540034 | 0.78 | DPP4 (0.51) | GPR119RORCDPP4MAPTTLR7 | |
| SCHEMBL25325368 | 0.78 | SLC6A4 (0.47) | RORCTACR1DPP4MAPTENPP2 | |
| SCHEMBL25325509 | 0.78 | SLC6A4 (0.47) | RORCTACR1DPP4TGFBR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | IDO1 3585/4885GPR119 144/4885RORC 4593/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | IDO1 3544/4885GPR119 192/4885RORC 3369/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | IDO1 3378/4885GPR119 53/4885RORC 4252/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | IDO1 3378/4885GPR119 53/4885RORC 4252/4885 |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, MGLL, LPL | IDO1 3714/4885GPR119 63/4885RORC 4211/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | IDO1 3378/4885GPR119 53/4885RORC 4252/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | IDO1 3378/4885GPR119 53/4885RORC 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.